Hodgkin Lymphoma (HL) is one of the curable malignant diseases. International prognostic score7 (IPS-7) was a valuable scoring system predicting FFP and OS in cases with HL. A simpler prognostic score: IPS-3 has been proposed 2 years ago and in this scoring system age and stage were found to be significant for FFP and age, stage and hemoglobin were found to be significant for OS. Here we evaluated IPS-3 new system in cases with HL.
364 patients with HL treated by ABVD have been included in this study. Two thirds of the patients had nodular sclerosing type HL, 76 had mixed cellularity type. Median follow up was 71 months.
Seven clinical parameters on the basis of the IPS-7 determined to be associated with adverse clinical outcome were evaluated. The prognostic ability of seven IPS factors was evaluated for both FFP and OS. A new 3-factor prognostic score (IPS-3 new) was constructed utilizing factors that were significant in multivariate Cox models: age>45 years, stage IV disease and lymphocytopenia were found to be independent factors. Thus IPS-3-new was constructed utilizing these 3 factors that were significant in multivariate Cox models. Lymphocytopenia was used instead of hemoglobin
The IPS-3 new covering lymphocytopenia instead of anemia besides age and stage factors on risk prediction for FFS and OS may provide a more accurate and reliable framework for risk assessment for the patients with HL.IPS-3 new is important due to the predictive property of lymphocytopenia in HL in immunotherapy era.
Clinical trial identification
Legal entity responsible for the study
Semra Paydas et al
All authors have declared no conflicts of interest.